Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8006 in advanced solid tumors
NCT05378737Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT8006 in solid tumor (advanced stage), ovarian cancer, endometrial cancer (EC) and 2 more (5 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose Limiting Toxicity at 21 days and Maximum Tolerated Dose at 21 days. Started Jul 2022; status: completed.
02
Drugs
BAT8006
03
Conditions
solid tumor (advanced stage)ovarian cancerendometrial cancer (EC)breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05378737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378737.